Attention AACR-NCI-EORTC Molecular Targets Conference Registrants - Activate Your Access

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 203 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 200 201 202 203 presentations: 1 to 25 of 5053
Keynote Lecture: Cell transfer immunotherapy targeting unique somatic mutations in cancer
Steven A. Rosenberg
National Cancer Inst., Bethesda, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 1:50 PM-4:10 PM
Resistance to PD-1 blockade in melanoma
Antoni Ribas
UCLA Medical Ctr., Los Angeles, CA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 4:30 PM-6:30 PM
Leveraging clinical genomics for candidate neoantigen discovery
Eliezer M. Van Allen
Dana-Farber Cancer Inst., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 8:00 AM-10:00 AM
Navigating the known and unknown challenges in the development of a selective NTRK inhibitor: The larotrectinib story
Keith T Flaherty
Massachusetts General Hosp. Cancer Ctr., Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 10:20 AM-12:20 PM
Job's dilemma for the genome: Why bad things happen to good chromosomes
David Pellman
Dana-Farber Cancer Institute, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 28, 2017 4:30 PM-6:00 PM
DNA damage signatures and practical use
Serena Nik-Zainal
Wellcome Trust Sanger Inst., Cambridge, United Kingdom
from 2017 Molecular Targets and Cancer Therapeutics conference on October 29, 2017 4:30 PM-6:00 PM
Leveraging the power of collaboration in a genomics tumor board: None of us is as smart as all of us
Janessa Laskin
BC Cancer Agency, Vancouver, BC, Canada
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 9:00 AM-10:30 AM
gMSK-IMPACT: Tumor/normal sequencing to guide diagnosis, treatment selection, and clinical trial enrollment
Michael F. Berger
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 9:00 AM-10:30 AM
Molecular tumor boards: Promise and reality
Elena Garralda
Spanish National Cancer Research Centre, Madrid, Spain
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 9:00 AM-10:30 AM
Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions
Shinichi Hasako
TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies
Leila M Boustany
CytomX Therapeutics, South San Francisco, CA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Neratinib has clinical activity in HER2-amplified breast cancer patients with tumors that have acquired activating mutations in HER2
Maurizio Scaltriti
Memorial Sloan-Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Krista Kinneer
MedImmune, Gaithersburg, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
AG-120 (ivosidenib), a first-in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma
Vikram Deshpande
Massachusetts General Hospital, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
Susan Chi
Dana-Farber Cancer Institute, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
First in human, dose escalation trial of the combination of dabrafenib, trametinib, and navitoclax in patients with BRAF mutant solid tumors
Ryan J Sullivan
Harvard Medical School/MGH, Boston, MA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Preliminary results from a phase 2 proof of concept trial of tipifarnib in tumors with HRAS mutations
Alan Ho
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Durable responses observed in recurrent high-grade glioma (rHGG) with Toca 511 and Toca FC treatment
Clark C Chen
University of Minnesota, Minneapolis, MN, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 10:50 AM-12:20 PM
Opening Remarks and Introduction
Judith S Sebolt-Leopold
Univ. of Michigan, Ann Arbor, MI, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 12:30 PM-1:30 PM
Keynote Address
Margaret Foti
American Association for Cancer Research, Philadelphia, PA, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 12:30 PM-1:30 PM
Keynote Lecture: PI 3-kinase links obesity, insulin resistance, and cancer
Lewis C. Cantley
Meyer Cancer Center, Weill Cornell Medical College, New York- Presbyterian Hospital, New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 1:50 PM-4:10 PM
Keynote Lecture: T-cell recognition of human cancer
Ton Schumacher
Netherlands Cancer Institute, Amsterdam, Netherlands
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 1:50 PM-4:10 PM
Resistance to PD-1 blockade in MSI-H tumors
Luis A. Diaz
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 4:30 PM-6:30 PM
Genomic and neoantigen landscape of response and resistance to immune checkpoint blockade
Victor E. Velculescu
Johns Hopkins Kimmel Comp. Cancer Ctr., Baltimore, MD, United States
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 4:30 PM-6:30 PM
Inactivation of DNA repair to improve immune surveillance
Alberto Bardelli
Univ. of Turin School of Medicine, Candiolo, Italy
from 2017 Molecular Targets and Cancer Therapeutics conference on October 27, 2017 4:30 PM-6:30 PM
<< first | < prev page: of 203 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 200 201 202 203 presentations: 1 to 25 of 5053